| Document |
Document Title |
|
WO/2023/137041A1 |
This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt, and/or hydrate, and/or cocrystal, and/or drug combination of the compound) that inhibit (e.g., antagonize) Stimulator of Interferon Genes...
|
|
WO/2023/134686A1 |
The present invention relates to the field of drug synthesis, particularly, to a preparation method for a 1,3,5-triazine derivative, more particularly, to a preparation method for 4-(tert-butoxyamino)-6-(6-(trifluoromethyl)pyridin-2-yl)-...
|
|
WO/2023/134608A1 |
Provided is a class of fused ring compounds that serve as HPK1 inhibitors. Specifically, provided are a compound represented by general formula (1), a preparation method therefor, and a use of the compound of general formula (1) and isom...
|
|
WO/2023/131969A1 |
The present invention relates to an improved process for the preparation of Luliconazole. The present invention also provides a novel intermediate 1-cyanomethylimidazole methanesulphonate of Formula (V), process for its preparation and i...
|
|
WO/2023/131667A1 |
Embodiments of the invention are directed to cooling compounds and cooling compositions having a unique cooling perception, as well as various edible, potable, and/or cosmetic products containing one or more cooling compounds having a ge...
|
|
WO/2023/133135A2 |
This invention is in the field of medicinal chemistry. In particular, the invention relates to a new class of small-molecules having a piperdinyl-formamide (or similar) structure which function as adrenoreceptor antagonists, and their us...
|
|
WO/2023/018471A9 |
N,N-disubstituted aminocarbonyl compounds and their use as integrin agonists for enhancing the binding of integrin-expressing cells to integrin-binding ligands or receptors.
|
|
WO/2023/131868A1 |
The present invention relates to heterocyclic compounds and methods which may be useful as inhibitors of GLUT9 for the treatment or prevention of hyperuricemia and gout.
|
|
WO/2023/132668A1 |
The present invention relates to a novel organic compound and an organic electroluminescent device using same, and more specifically, to an organic compound having excellent heat resistance, carrier transport ability, light emission capa...
|
|
WO/2023/132490A1 |
The present specification relates to a compound of chemical formula 1 and an organic light-emitting device comprising same.
|
|
WO/2023/131277A1 |
The present application belongs to the technical field of medicines, relates to an NLRP3 inflammasome inhibitor and the uses thereof, and particularly relates to a compound represented by general formula (A) or a pharmaceutically accepta...
|
|
WO/2023/132488A1 |
The present specification relates to a compound of chemical formula 1, and an organic light-emitting device comprising same.
|
|
WO/2023/132489A1 |
The present specification relates to a compound of chemical formula 1 and an organic light-emitting device comprising same.
|
|
WO/2023/133375A1 |
The present disclosure relates to macrocyclic compounds, pharmaceutical compositions containing macrocyclic compounds, and methods of using macrocyclic compounds to treat disease, such as autoimmune disease.
|
|
WO/2023/125716A1 |
Provided in the present invention are a class of quinoline compounds and a preparation method therefor, a pharmaceutical composition and the use thereof. Specifically, provided in the present invention are a compound as shown in formula ...
|
|
WO/2023/127809A1 |
In the production of agricultural and horticultural crops, etc., damages caused by pest insects, etc. are still significant, and, therefore, the development of novel pest control agents has been required due to factors such as the emerge...
|
|
WO/2023/125708A1 |
Disclosed in the present disclosure are a compound shown in formula (I), a racemate, stereoisomer, tautomer, isotopic label, solvate, pharmaceutically acceptable salt or prodrug thereof, a composition thereof, a preparation method theref...
|
|
WO/2023/128786A1 |
A family of triazole derivatives is described. Also described is the use of these triazole derivatives in treating or preventing viral infections, such as human immunodeficiency virus (HIV) infections, and the diseases caused by these in...
|
|
WO/2023/126297A1 |
The present invention relates to novel antifolate linker-drugs, conjugates comprising such antifolate linker-drugs, and the use thereof in the treatment of diseases, such as cancer, autoimmune and infectious diseases, optionally in combi...
|
|
WO/2023/125376A1 |
Provided are a fused bicyclic heteroaryl amide compound as a protein aggregation inhibitor, as well as the use of such compound in the treatment or prevention of neurodegenerative diseases characterized by protein aggregation, such as Al...
|
|
WO/2023/124205A1 |
The present application provides organic compounds, an organic electroluminescent device, and an electronic apparatus. The structure of the organic compounds is shown as formula 1, the organic compounds being used in an organic electrolu...
|
|
WO/2023/127805A1 |
In the production of crops in agriculture, horticulture, and the like, the occurrence of damage by pests and the like has been still a major issue, and therefore the development of new agricultural/horticultural pesticides has been deman...
|
|
WO/2023/128350A1 |
The present invention relates to a heteroaryl derivative, a stereoisomer thereof, a hydrate thereof, a solvate thereof, or a pharmaceutically acceptable salt thereof, a method for preparing same, and a pharmaceutical composition for prev...
|
|
WO/2023/121209A1 |
The present invention provides a novel compound and an organic light-emitting device using same.
|
|
WO/2023/122778A1 |
Disclosed herein are oxime compounds having the structure of Formula (I'): or a pharmaceutically acceptable salt, solvate, hydrate, isomer, tautomer, racemate, or isotope thereof, wherein L1, L2, R1, R2, R3, R4, R7, n, and r are as defin...
|
|
WO/2023/121062A1 |
The present invention provides a novel compound and an organic light emitting device using same.
|
|
WO/2023/121238A1 |
The present invention relates to a substituted heterocyclic derivative compound having a novel structure acting as a sterol regulatory element-binding protein-1 (SREBP1) inhibitor, a stereoisomer thereof, a hydrate thereof, or a pharmace...
|
|
WO/2023/118434A1 |
The present invention relates to novel pesticidally active amide compounds and in particular heteroaromatic amide compounds, to compositions comprising those compounds, and to their use in agriculture, for example in controlling insect p...
|
|
WO/2023/122276A1 |
Provided herein are small molecule active metabotropic glutamate subtype-2 and -3 receptor positive allosteric modulators (PAMS), compositions comprising the compounds, and methods of using the compounds and compositions comprising the c...
|
|
WO/2023/115394A1 |
A diarylamine compound and use thereof, a light extraction material, an electroluminescent device, and a display device. The structural general formula of the diarylamine compound is formula (I).
|
|
WO/2023/121071A1 |
The present invention provides a novel compound and an organic light-emitting device using same.
|
|
WO/2023/118968A2 |
Disclosed herein are methods of detecting xanthine oxidase expression in polycystic kidney disease, or methods of delaying the onset or treating polycystic kidney disease, or both. The inventors have made the remarkable discovery that ab...
|
|
WO/2023/120452A1 |
This SREBP-1 inhibitor has inhibitory activity against SREBP-1 and does not have inhibitory activity against SREBP-2, the SREBP-1 inhibitor containing, as an active ingredient, one or more compounds from among compounds represented by fo...
|
|
WO/2023/121096A1 |
The present invention provides a novel compound and an organic light-emitting device using same.
|
|
WO/2023/109954A1 |
Provided are safe and effective TYK2 inhibitors and pharmaceutical compositions, methods of preparation and use thereof against various TYK2-mediated diseases and disorders.
|
|
WO/2023/113575A1 |
The present specification relates to a compound of Formula 1 and an organic light-emitting device comprising same.
|
|
WO/2023/109120A1 |
TYK2 inhibitors, pharmaceutical compositions of these compounds,methods of preparation and the use thereof against various TYK2-mediated diseases and disorders.
|
|
WO/2023/109461A1 |
Disclosed in the present invention are a benzothiophene derivative, a preparation method therefor, and a use thereof. The structure of the benzothiophene derivative is as shown in general formula I, and the definition of each substituent...
|
|
WO/2023/113576A1 |
The present specification relates to a compound of chemical formula 1 and an organic light-emitting device comprising same.
|
|
WO/2023/111005A1 |
The present invention relates to a compound of formula (I) or an enantiomer, diastereomer, N-oxide, solvate, prodrug or pharmaceutically acceptable salt thereof. The present invention further relates to a compound of formula (I) for use ...
|
|
WO/2023/114823A1 |
The disclosure relates to compounds of Formula (I), which are RXFP1 agonists, compositions containing them, and methods of using them, for example, in the treatment of heart failure, fibrotic diseases, and related diseases such as lung d...
|
|
WO/2023/113389A1 |
The present invention provides: a heterocyclic compound which can significantly improve the lifespan, efficiency, electrochemical stability, and thermal stability of an organic light-emitting element; and an organic light-emitting elemen...
|
|
WO/2023/113577A1 |
The present specification relates to compounds of chemical formula 1 and chemical formula 2 and an organic light-emitting device comprising same.
|
|
WO/2023/110138A1 |
The invention relates to the compound of general formula (I) as novel inhibitors of transglutaminases, to methods for producing the inventive compounds, to pharmaceutical compositions containing said inventive compounds and to their use ...
|
|
WO/2023/112722A1 |
The present invention addresses the problem of providing: a compound suitably used for forming an optical anisotropic membrane that has excellent reverse wavelength dispersion property and moist heat durability; a polymerizable compositi...
|
|
WO/2023/114428A1 |
The disclosure provides heterocycle derivatives of Formula (I) for the inhibition of the oligosaccharyltransferase complex and the treatment of disease.
|
|
WO/2023/106973A1 |
The invention relates to a group of compounds which can be used as hepatoprotective agents. The invention further relates to a pharmaceutical composition which exhibits hepatoprotective activity and contains an effective amount of a comp...
|
|
WO/2023/106626A1 |
The present specification provides a heterocyclic compound, an organic light-emitting element comprising same, and a composition for an organic layer of the organic light-emitting element.
|
|
WO/2023/104201A1 |
An aryl C-glucoside derivative, a preparation method therefor and the use thereof. Specifically provided are an aryl C-glucoside derivative as shown in formula I, a tautomer thereof, a stereoisomer thereof, a prodrug thereof, or a pharma...
|
|
WO/2023/104023A1 |
A compound for specifically recognizing aluminum perchlorate, which compound is used as a mono-substituted pyrenyl-thiacalix[4]arene fluorescent probe. In the compound, a pyrenyl is introduced to a phenolic hydroxyl group of thiacalix[4]...
|
